» Articles » PMID: 26110761

Quantitative Assessment of Intra-Patient Variation in CD4+ T Cell Counts in Stable, Virologically-Suppressed, HIV-Infected Subjects

Overview
Journal PLoS One
Date 2015 Jun 26
PMID 26110761
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Counts of absolute CD4+ T lymphocytes (CD4+ T cells) are known to be highly variable in untreated HIV-infected individuals, but there are no data in virologically-suppressed individuals. We investigated CD4+ T cell variability in stable, virologically-suppressed, HIV-1 infected adults on combination antiretroviral therapy (cART).

Methods: From a large hospital database we selected patients with stable virological suppression on cART for >3 years with >10 CD4+ T cell measurements performed over a further >2 years; and a control group of 95 patients not on cART.

Results: We identified 161 HIV-infected patients on cART without active HCV or HBV infection, with stable virological suppression for a median of 6.4 years. Over the study period 88 patients had reached a plateau in their absolute CD4+ T cell counts, while 65 patients had increasing and 8 patients had decreasing absolute CD4+ T cell counts. In patients with plateaued CD4+ T cell counts, variability in absolute CD4+ T cell counts was greater than in percent CD4+ T cells (median coefficient of variation (CV) 16.6% [IQR 13.8-20.1%] and CV 9.6% [IQR 7.4-13.0%], respectively). Patients with increasing CD4+ T cell counts had greater variability in absolute CD4+ T cell counts than those with plateaued CD4 T cell counts (CV 19.5% [IQR 16.1-23.8%], p<0.001) while there was no difference in percent CD4+ T cell variability between the two groups. As previously reported, untreated patients had CVs significantly higher than patients on cART (CVs of 21.1% [IQR 17.2-32.0%], p<0.001 and 15.2% (IQR 10.7-20.0%), p<0.001, respectively). Age or sex did not affect the degree of CD4+ variation.

Conclusions: Adults with stable, virologically-suppressed HIV infection continue to have significant variations in individual absolute CD4+ T cell and percent CD4+ T cell counts; this variation can be of clinical relevance especially around CD4+ thresholds. However, the variation seen in individuals on cART is substantially less than in untreated subjects.

Citing Articles

Plasma concentrations of IL-6, MIP-1β, IP-10, and PTX-3 as predictors of the immunological response to antiretroviral treatment in people with HIV.

Mejias-Trueba M, Saborido-Alconchel A, Serna-Gallego A, Trujillo-Rodriguez M, Munoz-Muela E, Llaves-Flores S Front Immunol. 2024; 15:1447926.

PMID: 39267754 PMC: 11390504. DOI: 10.3389/fimmu.2024.1447926.


Ongoing HIV-1 evolution and reservoir reseeding in two elite controllers with genetically diverse peripheral proviral quasispecies.

de Azevedo S, Cortes F, Villela L, Hoagland B, Grinsztejn B, Veloso V Mem Inst Oswaldo Cruz. 2023; 118:e230066.

PMID: 37283423 PMC: 10292822. DOI: 10.1590/0074-02760230066.


Physical Activities and Associated Factors Among HIV/AIDS Patients: A Questionnaire Survey.

Zou Y, Sun P, Zhang Y, Li Y Patient Prefer Adherence. 2022; 16:1703-1712.

PMID: 35898922 PMC: 9309313. DOI: 10.2147/PPA.S360517.


Cumulative viral load as a predictor of CD4+ T-cell response to antiretroviral therapy using Bayesian statistical models.

Sempa J, Rossouw T, Lesaffre E, Nieuwoudt M PLoS One. 2019; 14(11):e0224723.

PMID: 31721805 PMC: 6853324. DOI: 10.1371/journal.pone.0224723.


Predictors of mortality within the first year of initiating antiretroviral therapy in urban and rural Kenya: A prospective cohort study.

Silverman R, John-Stewart G, Beck I, Milne R, Kiptinness C, McGrath C PLoS One. 2019; 14(10):e0223411.

PMID: 31584992 PMC: 6777822. DOI: 10.1371/journal.pone.0223411.


References
1.
Malone J, Simms T, Gray G, Wagner K, Burge J, Burke D . Sources of variability in repeated T-helper lymphocyte counts from human immunodeficiency virus type 1-infected patients: total lymphocyte count fluctuations and diurnal cycle are important. J Acquir Immune Defic Syndr (1988). 1990; 3(2):144-51. View

2.
Ford N, Stinson K, Davies M, Cox V, Patten G, Cragg C . Is it safe to drop CD4+ monitoring among virologically suppressed patients: a cohort evaluation from Khayelitsha, South Africa. AIDS. 2014; 28(14):2003-5. DOI: 10.1097/QAD.0000000000000406. View

3.
van Rood Y, Goulmy E, Blokland E, Pool J, van ROOD J, van Houwelingen H . Month-related variability in immunological test results; implications for immunological follow-up studies. Clin Exp Immunol. 1991; 86(2):349-54. PMC: 1554130. DOI: 10.1111/j.1365-2249.1991.tb05821.x. View

4.
Hoover D, Graham N, Chen B, Taylor J, Phair J, Zhou S . Effect of CD4+ cell count measurement variability on staging HIV-1 infection. J Acquir Immune Defic Syndr (1988). 1992; 5(8):794-802. View

5.
Laurence J . T-cell subsets in health, infectious disease, and idiopathic CD4+ T lymphocytopenia. Ann Intern Med. 1993; 119(1):55-62. DOI: 10.7326/0003-4819-119-1-199307010-00010. View